Kebilidi

eladocagene exuparvovec-tneq · ELADOCAGENE EXUPARVOVEC 560000000000 {GC}/mL · Suspension · Intracerebral · PTC Therapeutics, Inc.

NDC 52856-0601-01 · 1 VIAL, GLASS in 1 CARTON / .5 mL in 1 VIAL, GLASS · BLA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$3,950,000.00

Reported to Texas DSHS · 2026 annual filing · PTC Therapeutics

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: BLA125722
TE code: —
Approval date: —
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of eladocagene exuparvovec-tneq (Suspension)

Labeler	Strength	First seen	Last seen
PTC Therapeutics, Inc.	ELADOCAGENE EXUPARVOVEC 560000000000 {GC}/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Kebilidi — NDC 52856-0601-01," retrieved September 3, 2026, https://drugdashboards.com/drug/52856060101.

Free to cite with attribution — see how the data is put together.